Basic Information
RNALocate ID: | RLID:11002796 |
RNA Symbol: | hsa-miR-200a-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-200a-5p |
RNA ID: | miRBase:MIMAT0001620 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:11002792 | Exosome | Peripheral blood | 31746410 |
RLID:11002793 | Exosome | B cell line (Raji)|Jurkat-derived T cell line (J77cl20) | 21505438 |
RLID:11002794 | Exosome | Breast milk | 22211110 |
RLID:11002795 | Exosome | Brain tissue | 23382797 |
RLID:11002797 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000140 | Exosome | Colon tissue|Tongue tissue | |
RLID-D:11000456 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-200a-5p | Large cell neuroendocrine cancer | MNDR-E-MI-25945 |
MNDR | hsa-miR-200a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-25946 |
MNDR | hsa-miR-200a-5p | Ovarian clear cell carcinoma | MNDR-E-MI-25947 |
MNDR | hsa-miR-200a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-25948 |
MNDR | hsa-miR-200a-5p | Lymphoma | MNDR-E-MI-25949 |
MNDR | hsa-miR-200a-5p | Prostate cancer | MNDR-E-MI-25950 |
MNDR | hsa-miR-200a-5p | Gastric cancer | MNDR-E-MI-25951 |
MNDR | hsa-miR-200a-5p | Bladder cancer | MNDR-E-MI-25952 |
MNDR | hsa-miR-200a-5p | Parkinson disease | MNDR-E-MI-25953 |
MNDR | hsa-miR-200a-5p | Breast cancer | MNDR-E-MI-25954 |
MNDR | hsa-miR-200a-5p | Thyroid cancer | MNDR-E-MI-25955 |
MNDR | hsa-miR-200a-5p | Pituitary neoplasms | MNDR-E-MI-25956 |
MNDR | hsa-miR-200a-5p | Pancreatic cancer | MNDR-E-MI-25957 |
MNDR | hsa-miR-200a-5p | Rectum adenocarcinoma | MNDR-E-MI-25958 |
MNDR | hsa-miR-200a-5p | Nephroblastoma | MNDR-E-MI-25959 |
MNDR | hsa-miR-200a-5p | Colon cancer | MNDR-E-MI-25960 |
MNDR | hsa-miR-200a-5p | Colon adenocarcinoma | MNDR-E-MI-25961 |
MNDR | hsa-miR-200a-5p | Familial ovarian cancer | MNDR-E-MI-25962 |
MNDR | hsa-miR-200a-5p | Carcinoma ductal breast | MNDR-E-MI-25963 |
MNDR | hsa-miR-200a-5p | Invasive ductal carcinoma | MNDR-E-MI-25964 |
MNDR | hsa-miR-200a-5p | Glioma | MNDR-E-MI-25965 |
MNDR | hsa-miR-200a-5p | Breast carcinoma | MNDR-E-MI-25966 |
MNDR | hsa-miR-200a-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-25967 |
MNDR | hsa-miR-200a-5p | Cervical adenocarcinoma | MNDR-E-MI-25968 |
MNDR | hsa-miR-200a-5p | Gastric adenocarcinoma | MNDR-E-MI-25969 |
MNDR | hsa-miR-200a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-25970 |
MNDR | hsa-miR-200a-5p | Pituitary adenoma | MNDR-E-MI-25971 |
MNDR | hsa-miR-200a-5p | Lung squamous cell carcinoma | MNDR-E-MI-25972 |
MNDR | hsa-miR-200a-5p | Lung adenocarcinoma | MNDR-E-MI-25973 |
MNDR | hsa-miR-200a-5p | Ovarian carcinoma | MNDR-E-MI-25974 |
MNDR | hsa-miR-200a-5p | Bladder urothelial carcinoma | MNDR-E-MI-25975 |
MNDR | hsa-miR-200a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-25976 |
MNDR | hsa-miR-200a-5p | Carcinoma renal cell | MNDR-E-MI-25977 |
MNDR | hsa-miR-200a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-25978 |
MNDR | hsa-miR-200a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-25979 |
MNDR | hsa-miR-200a-5p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-25980 |
MNDR | hsa-miR-200a-5p | Cholangiocarcinoma | MNDR-E-MI-25981 |
MNDR | hsa-miR-200a-5p | Lung small cell carcinoma | MNDR-E-MI-25982 |
MNDR | hsa-miR-200a-5p | Synovial sarcoma | MNDR-E-MI-25983 |
MNDR | hsa-miR-200a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-25984 |
MNDR | hsa-miR-200a-5p | Testicular germ cell cancer | MNDR-E-MI-25985 |
MNDR | hsa-miR-200a-5p | Breast invasive carcinoma | MNDR-E-MI-25986 |
MNDR | hsa-miR-200a-5p | Hepatocellular carcinoma | MNDR-E-MI-25987 |
MNDR | hsa-miR-200a-5p | Familiar ovarian carcinoma | MNDR-E-MI-25988 |
MNDR | hsa-miR-200a-5p | Barrett's adenocarcinoma | MNDR-E-MI-25989 |
MNDR | hsa-miR-200a-5p | Tonsil cancer | MNDR-E-MI-25990 |
MNDR | hsa-miR-200a-5p | Skin cutaneous melanoma | MNDR-E-MI-25991 |
MNDR | hsa-miR-200a-5p | Skin melanoma | MNDR-E-MI-25992 |
MNDR | hsa-miR-200a-5p | Colorectal cancer | MNDR-E-MI-25993 |
MNDR | hsa-miR-200a-5p | Barrett's carcinogenesis | MNDR-E-MI-25994 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | CTNNB1 | Homo sapiens | RR00378128 |
TOP